Acute Retinal Necrosis: Is The Current Valacyclovir Regimen Adequate?

Area of Science:

• Ophthalmology
• Infectious Diseases
• Virology

Background:

• Acute Retinal Necrosis (ARN) is a severe intraocular inflammatory condition.
• ARN is typically caused by herpes simplex virus (HSV) or varicella-zoster virus (VZV).
• Antiviral therapy is the cornerstone of ARN management.

Observation:

• The current standard of care involves oral antiviral medications, commonly Valacyclovir.
• A recent case of ARN presented with unresponsiveness to standard oral Valacyclovir treatment.
• This observation suggests potential limitations of the current dosing regimen.

Findings:

• The efficacy of standard oral Valacyclovir doses in ARN may be insufficient in certain cases.
• Treatment resistance in ARN warrants a re-evaluation of therapeutic strategies.
• Dosage optimization or alternative treatment protocols may be necessary.

Implications:

• This case highlights the need for further investigation into optimal Valacyclovir dosing for ARN.
• Clinical guidelines may require revision to address treatment-resistant ARN.
• Improved treatment protocols could lead to better visual outcomes for ARN patients.